FOLR1 and cancer: Since folate receptor α (FOLR1) is low in normal tissues but is highly expressed in many human cancers, including multiple myelom (MM), lymphoma, and non-small cell lung cancer (NSCLC), folate-conjugating strategy is one of the commonly used drug delivery methods.